{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:02:43Z","timestamp":1787169763749,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"\n OBJECTIVES:<\/jats:title>\n \n Carbamazepine (CBZ), an anti-seizure drug, is widely prescribed for the management of focal seizures. At a given therapeutic dose, CBZ exhibits marked interindividual variation in the plasma CBZ levels. The aim wasto study the influence of EPHX1 c.337 T>C and\n UGT2B7<\/jats:italic>\n *2 genetic polymorphisms on plasma carbamazepine (CBZ) levels in persons with epilepsy (PWE) from South India.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n 115 PWE belong to South India origin who are on carbamazepine monotherapy were recruited. Genotyping of the two variants weredone using RT-PCR method. PWE who had seizure freedom for one year and their last dose which was not changed for one year duration were included and their plasma levels of CBZ and its active metabolite CBZ 10,11 epoxide were analysed by reverse phase HPLC.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n \n In EPHX1 c. 337 (T>C) polymorphism, the PWE carrying CC had lower plasma CBZ levels when compared to CT genotype (2.45 \u03bcg\/ml vs 3.15 \u03bcg\/ml. In\n UGT2B7<\/jats:italic>\n *2, PWE carrying homozygous mutant TT had higher levels when compared with CT (3.09 \u03bcg\/ml vs 2.74 \u03bcg\/ml) genotype but found no statistical significance. Mutant genotype of EPHX1 (CC) had higher metabolic ratio compared to TT genotype (1.33 vs 1.17) but not found to be statistically significant. Mutant genotype of\n UGT2B7<\/jats:italic>\n *2 (TT) was found to be having lower metabolic ratio when compared with CC genotype (1.18 vs 1.35;\n p<\/jats:italic>\n value =0.08).\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n \n PWE carrying EPHX1 c.337 T>C (rs1051740) and\n UGT2B7<\/jats:italic>\n *2 (rs7439366) genetic polymorphisms did not affect the plasma CBZ levels and metabolic ratio of PWE of South Indian origin. However, this finding should be confirmed in a larger sample size which may help in optimization and personalized CBZ therapy in South Indians.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijp.ijp_228_22","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:54:31Z","timestamp":1691369671000},"page":"149-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Genetic polymorphisms of microsomal epoxide hydrolase and UDP-glucuronosyltransferase (UGT) and its effects on plasma carbamazepine levels and metabolic ratio in persons with epilepsy of South India"],"prefix":"10.4103","volume":"55","author":[{"given":"Shravan","family":"Venkatraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesavan","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep Pankajakshan","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240903","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCPFAHVB26VVVTE","article-title":"Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays","volume":"133","author":"McMillin","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R2-2-20240903","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00216-006-0724-7","article-title":"Analysis of carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, in human plasma using high-performance liquid chromatography","volume":"386","author":"Oh","year":"2006","journal-title":"Anal Bioanal Chem"},{"key":"R3-2-20240903","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":"Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2217\/pgs.11.141","article-title":"Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization","volume":"13","author":"Hung","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R5-2-20240903","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1124\/jpet.104.073114","article-title":"N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7","volume":"311","author":"Staines","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-2-20240903","doi-asserted-by":"crossref","first-page":"e11662","DOI":"10.1097\/MD.0000000000011662","article-title":"Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine (Baltimore"},{"key":"R7-2-20240903","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature08365","article-title":"Reconstructing Indian population history","volume":"461","author":"Reich","year":"2009","journal-title":"Nature"},{"key":"R9-2-20240903","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","article-title":"dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation","volume":"9","author":"Sherry","year":"1999","journal-title":"Genome Res"},{"key":"R10-2-20240903","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmpt-2022-0157","article-title":"Influence of EPHX1 c. 337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: A cross-sectional genetic association study","volume":"38","author":"Venkatraman","year":"2023","journal-title":"Drug Metab Pers Ther"},{"key":"R11-2-20240903","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eplepsyres.2013.09.011","article-title":"Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy","volume":"107","author":"Yun","year":"2013","journal-title":"Epilepsy Res"},{"key":"R12-2-20240903","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s11096-019-00919-y","article-title":"Association between EPHX1 polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis","volume":"41","author":"Zhao","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"R13-2-20240903","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2217\/pgs.15.94","article-title":"Association between PK\/PD-involved gene polymorphisms and carbamazepine-individualized therapy","volume":"16","author":"Ma","year":"2015","journal-title":"Pharmacogenomics"},{"key":"R14-2-20240903","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/WNF.0000000000000172","article-title":"Therapeutic index estimation of antiepileptic drugs: A systematic literature review approach","volume":"39","author":"Greenberg","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"R15-2-20240903","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4103\/ijp.IJP_122_19","article-title":"Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population","volume":"51","author":"Ganesapandian","year":"2019","journal-title":"Indian J Pharmacol"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_228_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:01Z","timestamp":1787166781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_228_22"}},"subtitle":["A cross-sectional genetic association study"],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_228_22","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}